WASHINGTON, Sept. 14 (DC Times Online) — People taking popular GLP-1 medications such as Wegovy, Ozempic and Zepbound may need to pay attention to ongoing nausea, vomiting and sharp appetite loss — not because the drugs have been shown to cause a rare brain disorder, but because those symptoms can make it harder to get enough nutrients.
A reported analysis in the journal Clinical Nutrition identified 15 cases of Wernicke encephalopathy among people taking GLP-1 receptor agonists. The analysis used reports from the U.S. Food and Drug Administration’s Adverse Event Reporting System, published medical literature and records from the researchers’ medical center.
The findings show a possible safety signal, not a measure of the chance that an individual patient will develop the disorder. The researchers said the data cannot establish that the medications caused the cases. The analysis reportedly covered 195,979 cases, but the information available does not provide a population-wide risk estimate, a confirmed relative-risk number or an incidence rate.
What is Wernicke encephalopathy?
Wernicke encephalopathy is a neurological disorder caused by a serious deficiency of vitamin B1, also called thiamine. Reports about the study describe symptoms that can include confusion, trouble walking or keeping balance, unusual eye movements and vision changes.
Medical experts cited in reports about the analysis said untreated Wernicke encephalopathy can lead to permanent neurological damage or death. The research materials available for the study do not establish how often those outcomes occurred among all 15 reported cases.
A separate review of six published case reports involving people treated with semaglutide described one death, four cases of lasting memory problems and one full recovery. That review is a different body of evidence from the 15-case Clinical Nutrition analysis, and case reports cannot show how common a condition is among all people taking a drug.
How might appetite-suppressing drugs be involved?
GLP-1 drugs work in part by reducing appetite and slowing digestion. Nausea and vomiting are also reported side effects of these medicines. Researchers and clinicians cited in coverage of the analysis proposed that some patients may eat too little, lose weight quickly or become malnourished, reducing their intake of thiamine and other nutrients.
Achari, an expert quoted in the reports, said, “The drug shrinks your appetite. It doesn’t shrink your body’s requirements.” Achari also said that a person may eat very little without feeling hungry while still needing protein, vitamins and fluids.
That explanation is a proposed mechanism, not proof that GLP-1 medicines directly cause Wernicke encephalopathy. The reported cases involved semaglutide products, including Ozempic, Wegovy and Rybelsus; tirzepatide products, including Mounjaro and Zepbound; and at least one case involving liraglutide, sold as Victoza. The available information does not provide the full medical histories, doses or treatment timelines for all 15 cases.
Which patients may need closer attention?
Comments attributed to Achari identified persistent nausea or vomiting, rapid weight loss while eating little, previous bariatric surgery and heavy alcohol use as factors that may raise concern for thiamine deficiency. The reports did not establish that every person with one of these factors will develop Wernicke encephalopathy.
Symptoms such as confusion, new problems with balance or walking, abnormal eye movements or vision changes can have many possible causes. Because Wernicke encephalopathy can worsen without prompt treatment, people experiencing such symptoms should seek medical evaluation, according to the clinical experts cited in the reports.
Patients should not stop a prescribed GLP-1 medication solely because of the reported findings, experts said. Instead, persistent gastrointestinal symptoms, inability to eat or drink adequately, or unusually rapid weight loss are issues to discuss with the prescribing clinician. The available reports do not provide federal guidance requiring routine vitamin testing for all people taking GLP-1 drugs.
Dr. Goldman, quoted in one report, said GLP-1 medicines are important treatments for obesity and diabetes and that “the vast majority of patients take them safely.”
The reported study adds to questions about nutrition during rapid weight loss, but it does not show that a crisis is occurring among GLP-1 users. Further research would be needed to determine whether the drugs themselves increase the risk of Wernicke encephalopathy, or whether the reported cases reflect severe vomiting, poor intake, other medical conditions or a combination of factors.
